A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors. Conference Paper uri icon

authors

  • Lickliter, Jason D
  • Gan, Hui Kong
  • Meniawy, Tarek
  • Yang, Jason
  • Wang, Lai
  • Luo, Lusong
  • Lu, Ni
  • Millward, Michael

publication date

  • 2016